KYMR Stock — Kymera Therapeutics Inc.: Cash, EV, Pipeline

Share price

$118.89

Market cap

$9,886.2M

Cash

$691.0M

Enterprise value

$9,195.2M

Balance sheet

Cash	$691.0M
Debt	$0.0M
Net cash	$691.0M
Enterprise value	$9,195.2M
Basic shares	82.8M shares
Fully diluted shares	108.0M shares
Fully diluted market cap	$12,836.5M
Cash per share	$8.35

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading KYMR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	KT-579	Phase 1	Healthy Participants	—
Jul 13 - Aug 24	KT-621	Phase 2	Atopic Dermatitis	Q4 2026
Jan 12 - Feb 23	KT-621	Phase 2	Eosinophilic Asthma	—
Mar 29 - May 10	SAR447971	Phase 1	Hidradenitis; Healthy Volunteers	—
Jan 12 - Feb 23	KT-621	Phase 2	Asthma (Diagnosis)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

KT-621

Phase 2 · Active Modality: oral targeted protein degrader

Target STAT6

Indications

Moderate-to-severe atopic dermatitis (BROADEN2 Phase 2b) (Phase 2)
Moderate-to-severe asthma (BREADTH Phase 2b) (Phase 2)

Status note STAT6 program lead; oral degrader targeting the IL-4/IL-13 Type 2 inflammation pathway. Two Phase 2b trials recently initiated.

KT-579

Phase 1 · Active Modality: oral targeted protein degrader

Target IRF5

Indications

not disclosed (Stage not disclosed)

Status note IRF5 degrader program; Phase 1 in healthy volunteers recently initiated.

KT-485

Phase 1 · Active Modality: targeted protein degrader

Aliases SAR447971

Target IRAK4

Partnerships Sanofi: collaboration on IRAK4 degrader; Sanofi advances KT-485 into clinical testing; Kymera eligible for up to $955M additional development/commercial milestones + tiered royalties.

Status note Next-generation IRAK4 degrader; first participant dosed in first-in-human Phase 1 in Jun 2026 ($20M milestone).

KT-474

Phase 2 · Terminated Modality: targeted protein degrader

Target IRAK4

Partnerships Sanofi (collaboration)

Status note First-generation IRAK4 degrader; Sanofi stopped development in Jun 2025 after electing to advance KT-485 instead. Had reached Phase 2 in two undisclosed indications.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	KT-621
Lead indication	Atopic Dermatitis
Lead phase	Phase 2
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07217015	Phase 2	Active, not recruiting	Sponsor	KYMR	—	Atopic Dermatitis	Q4 2026
NCT07323654	Phase 2	Recruiting	Sponsor	KYMR	—	Eosinophilic Asthma	—
NCT07677059	Phase 2	Recruiting	Sponsor	KYMR	—	Asthma (Diagnosis)	—
NCT07412288	Phase 1	Recruiting	Sponsor	KYMR	—	Healthy Participants	—
NCT07629336	Phase 1	Recruiting	Collaborator	SNY	SNY	Hidradenitis; Healthy Volunteers	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Kymera Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	8,657,242	no change	4.97%	2026-08-14
Braidwell LP	378,163	+40,604	1.60%	2026-08-14
RTW Investments	240,000	no change	0.23%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

KYMR — Kymera Therapeutics Inc.